AstraZeneca considers potential merger with Bristol Myers Squibb

British pharmaceutical giant AstraZeneca is reportedly exploring a potential merger with American peer Bristol Myers Squibb, according to industry insiders. If realized, the proposed transaction could create a combined entity valued at approximately $400 billion, marking one of the largest corporate deals in the global pharmaceutical industry.

While details regarding the timeline or formal structure of the potential deal have not been made public, an agreement of this scale would dramatically reshape the market for oncology and immunology treatments worldwide. Neither AstraZeneca nor Bristol Myers Squibb has issued an official statement confirming the preliminary discussions or transaction terms.

Sources: FAZ.